Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,512.38 -3.89 -0.03%
TOPIX 1,171.40 -1.97 -0.17%
HANG SENG 22,760.24 64.23 0.28%

Rib-X Pharmaceuticals Announces New Executive Leadership and Board of Directors Appointments

  Rib-X Pharmaceuticals Announces New Executive Leadership and Board of
  Directors Appointments

  Mary Szela Appointed CEO, Dr. Eugene Sun as EVP, Research and Development,
    Michael Kenston as Chief Commercial Officer and Dr. Thomas Koestler as
                            Chairman of the Board

Business Wire

NEW HAVEN, Conn. -- April 3, 2013

Rib-X Pharmaceuticals, Inc. announced today new appointments to the executive
team and Board of Directors. Mary Szela has been appointed as Chief Executive
Officer, bringing 25 years of experience as an accomplished pharmaceutical
executive to the Company. Eugene Sun, M.D., has been appointed Executive Vice
President, Research and Development, bringing clinical and scientific
leadership and expertise to the Company. Michael Kenston has been appointed
Chief Commercial Officer, bringing a broad range of commercial, sales and
business development experience to the Company. Rib-X also announced today
that director, Thomas Koestler, Ph.D., has been appointed Chairman of the
Board. Ms. Szela, who joined the Company’s Board in January, will remain a

Commenting on these appointments, Kevin Ferro, CEO of Vatera Holdings LLC,
said, “The experience and expertise that Mary, Eugene, Mike and Tom bring to
Rib-X is impressive and represents a new beginning for the Company. We are
committed to ensuring that the novel and much needed antibiotics being
developed by a dedicated team of scientists at Rib-X are appropriately
resourced and brought to patients as soon as possible.”

"Rib-X is a highly energized biopharmaceutical company developing the right
products at the right time,” commented Ms. Szela. “Never has there been more
of a need for novel drugs to combat the proliferation of resistant pathogens
emerging worldwide. Rib-X has an exciting broad spectrum antibiotic poised to
enter multiple pivotal studies as well as a discovery platform based on Nobel
Prize-winning science that utilizes unprecedented structural insights to
target the vulnerabilities of pathogens.”

“Mary brings to Rib-X the leadership, product development and commercial
experience to build Rib-X into a leading specialty pharmaceutical company
delivering important new anti-infective agents to clinicians and patients,”
commented Dr. Koestler.

With more than two decades in senior roles at Abbott Laboratories (now
AbbVie), Ms. Szela most recently served as Senior Vice President, Global
Strategic Marketing and Services of the Pharmaceutical Products Group.
Previously, she served as Senior Vice President of U.S. Pharmaceuticals, an $8
billion business. For over seven years, she directed the development, launch
and growth of eight new pharmaceutical products, including leadership of
AbbVie’s flagship product, Humira.

Prior to 2001, Ms. Szela held a series of senior positions in Abbott’s
hospital products division where she was responsible for the peri-operative,
intensive care and pain management pharmaceutical business, the global
One-2-One outsourcing business, the critical care device business and the
vascular medicine pharmaceutical business.

Dr. Sun joins Rib-X following 17 years at Abbott Laboratories (now AbbVie),
where he most recently served as Corporate Vice President, Global
Pharmaceutical Clinical Development. In this role, Dr. Sun was responsible for
global clinical development, medical affairs, and clinical operations for all
pipeline compounds and marketed products across the pharmaceutical portfolio.
Prior to 2005, he held increasingly senior leadership positions in the R&D
organization. During his tenure at Abbott, Dr. Sun oversaw the development and
approval of multiple indications for Humira, and also led the development and
worldwide regulatory approval of the landmark HIV protease inhibitor Kaletra.

From 2001 to 2007, Dr. Sun served as the industry representative on the
Antiviral Drugs Advisory Committee of the Food and Drug Administration. Dr.
Sun received his undergraduate degree from Harvard University, his M.D. from
New York University School of Medicine, and completed his residency in
Internal Medicine and fellowship in Infectious Diseases at the University of
California, San Francisco.

“Dr. Sun has a unique ability to translate science into commercial
understanding and success,” said Ms. Szela. “Dr. Sun’s extensive clinical and
global regulatory experience across multiple therapeutic areas made him an
invaluable asset at Abbott where I had the privilege of working with him for
over ten years, and he will be instrumental to Rib-X as we continue the
clinical development of our pipeline and move towards approval and

Ms. Szela continued, “Delafloxacin represents an incredible opportunity to
address the high unmet medical need for better anti-infectives across multiple
indications in both IV and oral formulations. Mike brings over 20 years of
commercial experience and a diverse skillset to help Rib-X successfully
execute the commercial strategy for this promising candidate as well as for
our broader pipeline.”

Mr. Kenston joins Rib-X with over 20 years of commercial, sales and business
development experience. He most recently served as Vice President, Commercial
Analysis at Reata Pharmaceuticals where he led marketing research, forecasting
and SG&A optimization for the pre-launch of Bardoxolone Methyl. Prior to
Reata, Mr. Kenston was Vice President, Commercial Analysis and Business
Development Search & Evaluation for Lundbeck, Inc. (formerly Ovation
Pharmaceuticals). Mr. Kenston played an instrumental role in the sale of
Ovation to Lundbeck and continued on to lead the core commercial analysis
processes for the company. Mr. Kenston held several commercial roles over 16
years at Abbott Laboratories (now AbbVie), including Director level positions
in promotional analytics and marketing research and assessment. While at
Abbott, Mr. Kenston also served as Product Manager for the adult respiratory
segment of the antibiotic Biaxin.

Mr. Kenston has a Bachelor of Science degree from Northern Illinois University
and received his MBA in finance from Indiana University.

Dr. Koestler, an Executive Director of Vatera Holdings LLC, joined the Rib-X
Board in 2012. In his nearly 30-year career in the pharmaceutical industry,
Dr. Koestler established a track record of building high-performance teams
that drove global success in research and development. Most recently, he
served as Executive Vice President of Schering-Plough Corporation and
President of Schering-Plough Research Institute (SPRI), the pharmaceutical
Research and Development arm of Schering-Plough Corporation. Under his
leadership, the company developed an industry-leading pipeline that
contributed to the turnaround of the business. Dr. Koestler’s accomplishments
include over 80 product approvals including over 30 New Molecular
Entities/BLAs. Before joining Schering-Plough, Dr. Koestler was Senior Vice
President and Head of Global Regulatory Affairs for Pharmacia Corporation.
Prior to joining Pharmacia, he was Senior Vice President and Global Head, Drug
Regulatory Affairs, Compliance Assurance, Clinical Safety and Epidemiology for
Novartis. Before that appointment, he was Senior Director, Drug Regulatory
Affairs, at Ortho McNeil and a Director of Regulatory Affairs at Bristol-Myers
Squibb, Westwood Pharmaceuticals.

Dr. Koestler is also a member of the Board of Directors of Novo Nordisk A/S,
Momenta Pharmaceuticals Inc., Pearl Therapeutics Inc., ImmusanT Inc., and
Arisaph Pharmaceuticals Inc. Dr. Koestler also chairs the Scientific Advisory
Board of Bausch & Lomb. Dr. Koestler has a Bachelor of Science, Biology, from
Daemen College and a Ph.D. in Medicine & Pathology from the Roswell Park
Memorial Institute.

About Rib-X:

Rib-X Pharmaceuticals, Inc. is a biopharmaceutical company developing new
antibiotics to provide superior coverage, safety and convenience for the
treatment of serious and life-threatening infections. The Company's
proprietary drug discovery platform is based on Nobel Prize-winning science
and provides an atomic-level, three-dimensional understanding of interactions
between drug candidates and their bacterial targets and enables design of
antibiotics with enhanced characteristics. Rib-X’s lead program is
Delafloxacin, an enhanced spectrum IV/oral antibiotic intended for use as
first-line monotherapy to treat multiple bacterial diseases, which recently
completed a Phase 2b clinical trial for the treatment of acute bacterial skin
and skin structure infections. The Company's pipeline also includes its
preclinical RX-04 program and other discovery stage anti-infective programs.
Rib-X is privately held and backed among others by Vatera Healthcare and
Warburg Pincus. For more information, please visit


Rib-X Pharmaceuticals, Inc.
Bob Conerly, 203-624-5606
Media Relations
Kari Watson, 781-235-3060
Sponsored Links
Sponsored Links